No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia

Leukemia and Lymphoma

Volumn 46, Issue 6, 2005, Pages 893-897

  Jazbec, Janez ^a   Kitanovski, Lidija ^a   Aplenc, Richard ^b   Debeljak, Maruša ^a   Dolžan, Vita ^c  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Childhood leukemia; Methylenetetrahydrofolate reductase; Secondary neoplasm

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; ANTILEUKEMIC AGENT; CYSTEINE; DNA; METHOTREXATE; THREONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; BONE MARROW BIOPSY; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA ISOLATION; DRUG MEGADOSE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HODGKIN DISEASE; HUMAN; MALE; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLING; SECOND CANCER; SKIN TUMOR; SOFT TISSUE SARCOMA; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ALLELES; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; LEUKEMIA; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEOPLASMS, SECOND PRIMARY; ODDS RATIO; POLYMORPHISM, GENETIC; RISK; SEQUENCE ANALYSIS, DNA;

EID: 21844437612     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500086428     Document Type: Article

References (29)

1. Bhatia S, Buckley J, Robinson L. Second malignancies in childhood cancer. CCG Quart 1997;5:8-23.
2. de Vathaire F, Hawkins M, Campbell S, Oberlin O, Raquin MA, Schlinger JY, Shamsaladin A, Diallo I, Bell J, Grimaud E, Hardima C, Lagrange JL, Daly Schveitzer N, Panis X, Zucker JM, Sancho-Garnier H, Eschwege F, Chavadura J, Lemerle J. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer 1999;79:1884-1893.
3. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Pui CH, Raimondi SC, Relling MV. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002;12:605-611.
4. Green DM, Hyland A, Barcos MP, Reynolds JA, Lee RJ, Hall BC, Zevon MA. Second malignant neoplasm after treatment for Hodkin's disease in childhood and adolescence. J Clin Oncol 2000;18:1492-1499.
5. Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993;85:1932-1937.
6. Ching-Hon P, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT, Crist WM. Acute myeloid leukemia in children treated with epipodophylotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-1687.
7. Leung W, Sandlund JT, Hudson MM, Zhou Y, Hancock ML, Zhu Y, Ribeiro RC, Rubnitz JE, Kun LE, Razzouk B, Evans WE, Pui CH. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001;92:1959-1966.
8. Gono T, Shimojima Y, Hoshi K, Yamamoto K, Tokuda T, Shikama N, Matsuda M, Ikeda S. Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate. Intern Med 2004;43:135-138.
9. Stewart M, Malakovska V, Krishnan J, Lessin L, Barth W. Lymphoma in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with rituximab. Ann Rheum Dis 2001;60:892-893.
10. Mariette X, Calaz-Hatem D, Warszawski J, Loite F, Balandraun N, Sibila J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-3915.
11. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. Arthritis Rheumat 2004;50:1740-1751.
12. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491.
13. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR. Association of CYP3A4 genotype with treatment related leukemia. Proc Natl Acad Sci USA 1998;95:13176-13181.
14. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui CH. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;3:354:34-39.
15. Duthie SJ, Narayanan S, Brand GM, Pirie L, Grant G. Impact of folate deficiency on DNA stability. J Nutrit 2002;132:2444S-2449S.
16. Frost P. Blom HJ, Milos R, Goyette P, Shepard CA, Metthews RG. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
17. Weisberg I, Tran P, Christensen B, Sibiani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase gene associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-172.
18. Schneider JA, Rees DC, Liu YT, Cleg JB. Worldwide distribution of common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998;62:1258-1265.
19. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenom 2001;1:189-201.
20. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Catrwright RA, Morgan G. Polymorphysms in the methylenetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adoults. PNAS 1999;96:12810-12815.
21. Krajinovic M, Lamote S, Labuda D, Lemieux-Blanchard E, Theoret Y, Moghrabi A, Sinnet D. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004;103:252-257.
22. Matuso K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, Kondoh E, Maeda S, Asakura S, Kaba S, Nakamura S, Seto M, Morishima Y, Tajima K. Association between polymorphism of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-3209.
23. Song C, Xing D, Tan W, Lin D. Methylenetetrahydrofolate reductase polymorphism increase risk of esophageal squamous cell carcinoma in chinese population. Cancer Res 2001;61:3272-3275.
24. Shen H, Spitz MR, Wang LE, Hong WK, Wei Q. Polymorphisms of methyleneterahydrofolate reductase and risk of lung cancer: a case control study. Cancer Epidemiol Biomark Prevent 2001;10:397-401.
25. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, Ariail KS, Keener CL, Li S, Liu H, Farin FM, Potter JD. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;1:98:231-234.
26. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions and risk of colorectal cancer. Cancer Res 1997;57:1098-1102.
27. Aplenc R, Orudjev E, Swoyer J, Manke B, Rebbeck T. Differential bone marrow aspirate DNA yields from commercial extraction kits. Leukemia 2002;16:1865-1866.
28. Yi P, Pogrinbny IP, James SJ. Multiplex PCR for simultaneus detection of 667C > T and 1298A > C polymorphisms in methylentetrahydrofolate reductase gene for population studies of cancer risk. Cancer Letts 2002;181:209-213.
29. Jazbec J, Ečimovič P, Jereb B. Second neoplasms after treatment of cancer in childhood. Pediatr Blood Cancer 2004;42:574-581.